<Suppliers Price>

Petosemtamab

Names

[ CAS No. ]:
2213450-26-9

[ Name ]:
Petosemtamab

Biological Activity

[Description]:

Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)[1][2].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> JAK/STAT Signaling >> EGFR
Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

[Target]

EGFR:0.22 nM (Kd)

LGR5:0.85 nM (Kd)


[In Vitro]

MCLA-158 (1 µg/mL, 24 or 72 h) leads to EGFR degradation in EGFR+/LGR5+ colorectal cancer organoids[2]. Western Blot Analysis[2] Cell Line: P18T (KRAS WT), C55T (KRAS G12V) and C82N (normal) organoids Concentration: 1 µg/mL Incubation Time: 1, 6, 24, 72 h Result: Time-dependently degraded EGFR.

[In Vivo]

MCLA-158 (25 mg/kg/week, i.v., for 6 weeks) leads to tumor regression in esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2]. Animal Model: Esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2] Dosage: 25 mg/kg/week Administration: Intravenous injection (i.v.) for 6 weeks. Result: Inhibited tumor growth.

[References]

[1]. Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement): P185.

[2]. Guillem Argiles, et al. Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). Journal of Clinical Oncology 39, no. 3_suppl

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.